RxDoctor Payments Data

James Marroquin, MD

Internal Medicine · Austin, TXNPI 1902014392

Payments from drug & device makers

$8,260in general payments, 2019–2025

Across 450 payments — averaging $18.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$994
  • Lilly USA, LLC$783
  • Novo Nordisk$757
  • AstraZeneca$587
  • GSK$487
  • Bayer$454
  • plus $4K from 39 others

What the payments were for

  • Food & beverage$8,20099%
  • Education$601%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,260 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$231,018
Medicare patients
263
Services billed
3,092

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban142$150,861
OzempicSemaglutide79$86,126
MyrbetriqMirabegron118$75,201
JardianceEmpagliflozin75$74,787
MounjaroTirzepatide45$62,331
Repatha SureclickEvolocumab59$45,577
Teriparatide12$45,354
XareltoRivaroxaban37$34,351
GemtesaVibegron44$33,558
FarxigaDapagliflozin Propanediol36$30,231
TrulicityDulaglutide27$26,874
KerendiaFinerenone34$25,941
CreonLipase/Protease/Amylase18$23,460
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$22,192
Mirabegron ErMirabegron21$9,445

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$212$155,149209 claims
Lilly USA, LLCMounjaro, Trulicity$783$89,20672 claims
Novo NordiskOzempic$757$86,12679 claims
Boehringer IngelheimJardiance, Combivent Respimat$376$80,73486 claims
Astellas Pharma US IncMyrbetriq$227$75,201118 claims
Alvogen IncTeriparatide$26$45,35412 claims
AbbVieCreon, Namzaric, Synthroid$357$36,63197 claims
Johnson & JohnsonXarelto$87$34,35137 claims
Sumitomo Pharma America, Inc.Gemtesa$365$33,55844 claims
AstraZenecaFarxiga$587$30,23136 claims
BayerKerendia$454$25,94134 claims
GSKTrelegy Ellipta$487$22,19227 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →